Initiator Pharma Q2: Silent advancements - Redeye

Redeye provides a research update following the Q2 report published by Initiator Pharma earlier today. The report did not include any significant surprises as the company continues to operate at a low cash burn, showing promise for the financial runway ahead. Following the recent patent application for pudafensine, we restate that the full priority for H2 2024 will be to find a licensing partner for the candidate. We reiterate our fair value range with a base case valuation of SEK24.

Länk till analysen i sin helhet: https://www.redeye.se/research/1034355/initiator-pharma-q2-silent-advancements?utm_source=finwire&utm_medium=RSS